 Daniel Pollyea
Concepts (466)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 111 | 2024 | 592 | 25.760 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 37 | 2025 | 215 | 9.850 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 49 | 2025 | 1556 | 8.150 |
Why?
| | Sulfonamides | 32 | 2025 | 495 | 7.930 |
Why?
| | Azacitidine | 23 | 2024 | 139 | 6.590 |
Why?
| | Myelodysplastic Syndromes | 28 | 2023 | 129 | 6.420 |
Why?
| | Mutation | 35 | 2024 | 3710 | 3.160 |
Why?
| | Isocitrate Dehydrogenase | 13 | 2022 | 52 | 3.010 |
Why?
| | Hematologic Neoplasms | 10 | 2023 | 140 | 2.880 |
Why?
| | Antineoplastic Agents | 24 | 2024 | 2054 | 2.830 |
Why?
| | Neoplastic Stem Cells | 14 | 2025 | 379 | 2.420 |
Why?
| | Hematopoietic Stem Cell Transplantation | 17 | 2024 | 572 | 2.360 |
Why?
| | Neoplasm, Residual | 7 | 2024 | 120 | 2.320 |
Why?
| | Triazines | 7 | 2021 | 38 | 1.990 |
Why?
| | Aminopyridines | 7 | 2021 | 97 | 1.920 |
Why?
| | Graft vs Host Disease | 9 | 2024 | 240 | 1.730 |
Why?
| | Remission Induction | 15 | 2021 | 271 | 1.550 |
Why?
| | RNA Splicing Factors | 3 | 2020 | 52 | 1.460 |
Why?
| | Prognosis | 27 | 2024 | 3773 | 1.440 |
Why?
| | Humans | 155 | 2025 | 129271 | 1.380 |
Why?
| | Aged | 58 | 2024 | 22032 | 1.310 |
Why?
| | Aged, 80 and over | 32 | 2024 | 7055 | 1.280 |
Why?
| | Phosphoproteins | 3 | 2020 | 332 | 1.260 |
Why?
| | Cytarabine | 8 | 2022 | 57 | 1.250 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2020 | 958 | 1.180 |
Why?
| | Leukemia | 4 | 2023 | 229 | 1.140 |
Why?
| | Treatment Outcome | 33 | 2024 | 10202 | 1.070 |
Why?
| | Salvage Therapy | 5 | 2023 | 133 | 1.030 |
Why?
| | Clonal Evolution | 2 | 2017 | 39 | 1.000 |
Why?
| | Cord Blood Stem Cell Transplantation | 4 | 2024 | 99 | 0.980 |
Why?
| | Drug Resistance, Neoplasm | 9 | 2025 | 756 | 0.920 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2022 | 64 | 0.910 |
Why?
| | Nuclear Proteins | 5 | 2018 | 659 | 0.900 |
Why?
| | fms-Like Tyrosine Kinase 3 | 4 | 2017 | 46 | 0.900 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 278 | 0.890 |
Why?
| | Molecular Targeted Therapy | 7 | 2024 | 390 | 0.850 |
Why?
| | Middle Aged | 46 | 2024 | 31091 | 0.850 |
Why?
| | Carrier Proteins | 3 | 2017 | 742 | 0.840 |
Why?
| | Transplantation Conditioning | 9 | 2024 | 166 | 0.830 |
Why?
| | Leukemia, Neutrophilic, Chronic | 3 | 2019 | 5 | 0.820 |
Why?
| | Dancing | 1 | 2022 | 14 | 0.790 |
Why?
| | Thrombocytopenia | 2 | 2023 | 186 | 0.780 |
Why?
| | Spliceosomes | 2 | 2020 | 46 | 0.780 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 4 | 2018 | 232 | 0.750 |
Why?
| | Anemia | 2 | 2020 | 160 | 0.750 |
Why?
| | Enzyme Inhibitors | 5 | 2020 | 827 | 0.750 |
Why?
| | Febrile Neutropenia | 1 | 2020 | 3 | 0.710 |
Why?
| | Splicing Factor U2AF | 2 | 2023 | 16 | 0.680 |
Why?
| | Male | 55 | 2024 | 63517 | 0.670 |
Why?
| | Female | 60 | 2024 | 68556 | 0.660 |
Why?
| | Receptors, Colony-Stimulating Factor | 2 | 2017 | 6 | 0.650 |
Why?
| | Serine-Arginine Splicing Factors | 2 | 2019 | 22 | 0.650 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 6 | 2025 | 118 | 0.640 |
Why?
| | Adult | 33 | 2024 | 35497 | 0.620 |
Why?
| | Phenylurea Compounds | 7 | 2020 | 89 | 0.600 |
Why?
| | DNA Methylation | 3 | 2019 | 610 | 0.600 |
Why?
| | Staurosporine | 1 | 2017 | 20 | 0.580 |
Why?
| | Stem Cells | 3 | 2020 | 574 | 0.580 |
Why?
| | Benzimidazoles | 6 | 2020 | 162 | 0.550 |
Why?
| | Protein Kinase Inhibitors | 10 | 2025 | 890 | 0.530 |
Why?
| | Gene Frequency | 2 | 2017 | 502 | 0.520 |
Why?
| | Recurrence | 9 | 2023 | 1005 | 0.510 |
Why?
| | Monocytes | 2 | 2018 | 551 | 0.500 |
Why?
| | Glycine | 4 | 2021 | 165 | 0.500 |
Why?
| | Neoplasms, Plasma Cell | 1 | 2015 | 7 | 0.500 |
Why?
| | Leukocytosis | 1 | 2015 | 32 | 0.500 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2018 | 485 | 0.490 |
Why?
| | Skin Neoplasms | 1 | 2023 | 824 | 0.490 |
Why?
| | Gene Expression | 1 | 2020 | 1466 | 0.490 |
Why?
| | Retrospective Studies | 16 | 2024 | 14461 | 0.480 |
Why?
| | Signal Transduction | 9 | 2022 | 4926 | 0.480 |
Why?
| | Precision Medicine | 1 | 2018 | 386 | 0.470 |
Why?
| | Epigenesis, Genetic | 1 | 2019 | 616 | 0.460 |
Why?
| | Computational Biology | 1 | 2019 | 595 | 0.460 |
Why?
| | Patient Safety | 1 | 2018 | 285 | 0.460 |
Why?
| | Pyridines | 5 | 2023 | 478 | 0.450 |
Why?
| | Maximum Tolerated Dose | 5 | 2019 | 193 | 0.450 |
Why?
| | Oxidative Phosphorylation | 6 | 2024 | 187 | 0.450 |
Why?
| | Medical Oncology | 4 | 2023 | 270 | 0.450 |
Why?
| | Induction Chemotherapy | 3 | 2024 | 70 | 0.430 |
Why?
| | Clinical Trials, Phase I as Topic | 2 | 2024 | 50 | 0.430 |
Why?
| | Hematopoiesis | 4 | 2020 | 183 | 0.430 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2024 | 93 | 0.430 |
Why?
| | Neoplasm Proteins | 4 | 2022 | 422 | 0.430 |
Why?
| | Pyrazoles | 1 | 2017 | 404 | 0.420 |
Why?
| | Apoptosis | 4 | 2018 | 2499 | 0.420 |
Why?
| | Germ-Line Mutation | 3 | 2022 | 140 | 0.410 |
Why?
| | Immunity, Innate | 1 | 2019 | 803 | 0.410 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2021 | 2011 | 0.400 |
Why?
| | Leukemia, Myeloid | 1 | 2012 | 45 | 0.400 |
Why?
| | Glutarates | 1 | 2012 | 8 | 0.400 |
Why?
| | DNA (Cytosine-5-)-Methyltransferases | 2 | 2018 | 31 | 0.390 |
Why?
| | RNA Splicing | 4 | 2023 | 260 | 0.370 |
Why?
| | Neutrophils | 2 | 2023 | 1207 | 0.370 |
Why?
| | Drug Delivery Systems | 1 | 2014 | 333 | 0.360 |
Why?
| | Antibodies, Monoclonal, Humanized | 7 | 2023 | 758 | 0.360 |
Why?
| | Follow-Up Studies | 8 | 2020 | 4887 | 0.360 |
Why?
| | Young Adult | 15 | 2024 | 12392 | 0.360 |
Why?
| | Neoplasms | 4 | 2018 | 2449 | 0.350 |
Why?
| | United States Food and Drug Administration | 2 | 2022 | 204 | 0.350 |
Why?
| | Aldehyde Dehydrogenase | 3 | 2017 | 101 | 0.340 |
Why?
| | Survival Rate | 10 | 2020 | 1869 | 0.340 |
Why?
| | Leukocyte Count | 2 | 2024 | 326 | 0.330 |
Why?
| | Rhipicephalus sanguineus | 1 | 2009 | 1 | 0.330 |
Why?
| | Triatoma | 1 | 2009 | 5 | 0.330 |
Why?
| | Wasps | 1 | 2009 | 8 | 0.330 |
Why?
| | Insect Bites and Stings | 1 | 2009 | 11 | 0.330 |
Why?
| | Syncope | 1 | 2009 | 51 | 0.320 |
Why?
| | Electron Transport Complex II | 2 | 2019 | 24 | 0.310 |
Why?
| | Cytokines | 4 | 2020 | 2013 | 0.310 |
Why?
| | Kaplan-Meier Estimate | 5 | 2020 | 851 | 0.310 |
Why?
| | Mutant Proteins | 2 | 2019 | 99 | 0.300 |
Why?
| | Risk Assessment | 5 | 2024 | 3233 | 0.300 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2010 | 146 | 0.300 |
Why?
| | Administration, Oral | 4 | 2018 | 785 | 0.300 |
Why?
| | Cell Self Renewal | 2 | 2019 | 53 | 0.300 |
Why?
| | Proto-Oncogene Proteins | 2 | 2018 | 635 | 0.300 |
Why?
| | Acute Disease | 3 | 2023 | 978 | 0.300 |
Why?
| | Anaphylaxis | 1 | 2009 | 98 | 0.300 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2024 | 1365 | 0.300 |
Why?
| | Bone Marrow | 4 | 2017 | 271 | 0.290 |
Why?
| | Transplantation, Homologous | 6 | 2022 | 400 | 0.290 |
Why?
| | Immunotherapy, Adoptive | 2 | 2022 | 295 | 0.290 |
Why?
| | Survival Analysis | 6 | 2020 | 1269 | 0.280 |
Why?
| | Gene Expression Regulation, Leukemic | 3 | 2016 | 50 | 0.280 |
Why?
| | Drug Administration Schedule | 4 | 2020 | 768 | 0.270 |
Why?
| | Disease-Free Survival | 5 | 2022 | 645 | 0.270 |
Why?
| | Mitochondria | 3 | 2024 | 877 | 0.260 |
Why?
| | Thrombocythemia, Essential | 2 | 2016 | 7 | 0.260 |
Why?
| | Primary Myelofibrosis | 2 | 2016 | 9 | 0.260 |
Why?
| | Polycythemia Vera | 2 | 2016 | 12 | 0.260 |
Why?
| | Animals | 26 | 2025 | 35309 | 0.250 |
Why?
| | Clinical Trials as Topic | 4 | 2020 | 1004 | 0.250 |
Why?
| | Hematopoietic Stem Cells | 3 | 2022 | 381 | 0.250 |
Why?
| | Cytogenetic Analysis | 2 | 2022 | 32 | 0.240 |
Why?
| | Mice | 18 | 2025 | 16915 | 0.240 |
Why?
| | Influenza Vaccines | 1 | 2010 | 532 | 0.240 |
Why?
| | Biomarkers, Tumor | 4 | 2019 | 1173 | 0.230 |
Why?
| | DEAD-box RNA Helicases | 2 | 2015 | 66 | 0.230 |
Why?
| | Transplantation, Haploidentical | 1 | 2024 | 21 | 0.230 |
Why?
| | Stem Cell Transplantation | 3 | 2023 | 164 | 0.220 |
Why?
| | Allografts | 2 | 2021 | 136 | 0.220 |
Why?
| | Influenza, Human | 1 | 2010 | 601 | 0.220 |
Why?
| | Azetidines | 1 | 2024 | 40 | 0.220 |
Why?
| | Antibodies, Monoclonal | 4 | 2017 | 1367 | 0.210 |
Why?
| | DNA Mutational Analysis | 4 | 2019 | 385 | 0.210 |
Why?
| | Finland | 1 | 2023 | 90 | 0.210 |
Why?
| | DNA-Binding Proteins | 1 | 2010 | 1446 | 0.210 |
Why?
| | RNA, Messenger | 1 | 2010 | 2703 | 0.210 |
Why?
| | Drug Therapy, Combination | 4 | 2022 | 1040 | 0.210 |
Why?
| | Disease Management | 4 | 2021 | 588 | 0.200 |
Why?
| | Antibodies, Neoplasm | 3 | 2007 | 34 | 0.200 |
Why?
| | Uncertainty | 1 | 2023 | 116 | 0.200 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 2 | 2019 | 17 | 0.200 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2022 | 131 | 0.200 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2023 | 77 | 0.200 |
Why?
| | Hematology | 1 | 2022 | 14 | 0.190 |
Why?
| | Thalidomide | 2 | 2012 | 32 | 0.190 |
Why?
| | Piperidines | 1 | 2024 | 198 | 0.190 |
Why?
| | Myeloproliferative Disorders | 1 | 2022 | 26 | 0.190 |
Why?
| | Amino Acid Transport System ASC | 1 | 2022 | 12 | 0.190 |
Why?
| | Succinate Dehydrogenase | 2 | 2019 | 44 | 0.190 |
Why?
| | Disease Progression | 3 | 2023 | 2630 | 0.190 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2022 | 46 | 0.190 |
Why?
| | Receptors, Mitogen | 1 | 2021 | 9 | 0.180 |
Why?
| | Polymerase Chain Reaction | 1 | 2024 | 1036 | 0.180 |
Why?
| | Lectins, C-Type | 1 | 2021 | 71 | 0.180 |
Why?
| | Erythroblasts | 1 | 2020 | 15 | 0.180 |
Why?
| | Blood Cell Count | 1 | 2020 | 52 | 0.180 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 327 | 0.170 |
Why?
| | Lipase | 1 | 2020 | 65 | 0.170 |
Why?
| | STAT3 Transcription Factor | 1 | 2022 | 194 | 0.170 |
Why?
| | Histocompatibility Testing | 2 | 2019 | 120 | 0.170 |
Why?
| | Inflammation Mediators | 2 | 2020 | 505 | 0.170 |
Why?
| | Tumor Lysis Syndrome | 1 | 2019 | 8 | 0.170 |
Why?
| | Dendritic Cells | 1 | 2023 | 479 | 0.160 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2021 | 132 | 0.160 |
Why?
| | Immunoconjugates | 1 | 2021 | 103 | 0.160 |
Why?
| | Leukopoiesis | 1 | 2019 | 11 | 0.160 |
Why?
| | Fatty Acids | 2 | 2020 | 427 | 0.160 |
Why?
| | NADPH Oxidase 2 | 1 | 2019 | 38 | 0.160 |
Why?
| | Myeloid Progenitor Cells | 1 | 2019 | 17 | 0.160 |
Why?
| | Age Factors | 5 | 2022 | 3140 | 0.160 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2019 | 24 | 0.160 |
Why?
| | Mycoses | 1 | 2019 | 71 | 0.160 |
Why?
| | K562 Cells | 1 | 2019 | 86 | 0.160 |
Why?
| | RAW 264.7 Cells | 1 | 2019 | 49 | 0.160 |
Why?
| | Genetic Testing | 2 | 2019 | 428 | 0.160 |
Why?
| | Genomics | 3 | 2019 | 717 | 0.160 |
Why?
| | Tricarboxylic Acids | 1 | 2018 | 10 | 0.160 |
Why?
| | Ketoglutaric Acids | 1 | 2018 | 15 | 0.150 |
Why?
| | Antibodies | 1 | 2021 | 398 | 0.150 |
Why?
| | United States | 5 | 2023 | 13828 | 0.150 |
Why?
| | Hematologic Diseases | 1 | 2019 | 61 | 0.150 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 509 | 0.150 |
Why?
| | Antibiotic Prophylaxis | 1 | 2019 | 101 | 0.150 |
Why?
| | Cell Line, Tumor | 7 | 2025 | 3202 | 0.150 |
Why?
| | Amino Acids | 2 | 2020 | 486 | 0.150 |
Why?
| | Mitochondrial Proteins | 2 | 2018 | 248 | 0.150 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2018 | 91 | 0.150 |
Why?
| | Thiotepa | 1 | 2018 | 20 | 0.150 |
Why?
| | Calcium | 1 | 2024 | 1212 | 0.150 |
Why?
| | Lymphoma | 2 | 2017 | 196 | 0.150 |
Why?
| | Trees | 1 | 2018 | 69 | 0.140 |
Why?
| | Cysteine | 1 | 2019 | 195 | 0.140 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2014 | 69 | 0.140 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 38 | 0.140 |
Why?
| | Confidence Intervals | 1 | 2018 | 316 | 0.140 |
Why?
| | HLA-DR Antigens | 1 | 2018 | 223 | 0.140 |
Why?
| | Hematinics | 1 | 2017 | 20 | 0.130 |
Why?
| | Infusions, Intravenous | 1 | 2018 | 399 | 0.130 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2018 | 191 | 0.130 |
Why?
| | Hedgehog Proteins | 1 | 2018 | 187 | 0.130 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 66 | 0.130 |
Why?
| | Periodicals as Topic | 1 | 2019 | 204 | 0.130 |
Why?
| | Cohort Studies | 5 | 2022 | 5409 | 0.130 |
Why?
| | Unrelated Donors | 1 | 2016 | 36 | 0.130 |
Why?
| | Genome, Human | 1 | 2018 | 392 | 0.130 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2016 | 56 | 0.130 |
Why?
| | Energy Metabolism | 2 | 2019 | 873 | 0.130 |
Why?
| | Geriatric Assessment | 1 | 2018 | 205 | 0.130 |
Why?
| | Pyrimidines | 2 | 2017 | 459 | 0.130 |
Why?
| | Nitriles | 1 | 2017 | 172 | 0.130 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2016 | 79 | 0.130 |
Why?
| | Oncogene Proteins | 1 | 2016 | 55 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 2 | 2022 | 2276 | 0.120 |
Why?
| | Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 14 | 0.120 |
Why?
| | Mice, Inbred NOD | 4 | 2019 | 588 | 0.120 |
Why?
| | Lipopolysaccharides | 1 | 2019 | 877 | 0.120 |
Why?
| | Electronic Health Records | 1 | 2023 | 970 | 0.120 |
Why?
| | Methyltransferases | 1 | 2016 | 70 | 0.120 |
Why?
| | Adolescent | 7 | 2024 | 20315 | 0.120 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 232 | 0.120 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 70 | 0.120 |
Why?
| | Biomarkers | 3 | 2022 | 3968 | 0.120 |
Why?
| | Hemoglobins | 2 | 2018 | 339 | 0.120 |
Why?
| | Oligomycins | 1 | 2014 | 7 | 0.120 |
Why?
| | Chromosome Aberrations | 1 | 2015 | 148 | 0.120 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 17 | 0.120 |
Why?
| | Homeostasis | 1 | 2018 | 605 | 0.120 |
Why?
| | Cell Survival | 4 | 2022 | 1075 | 0.110 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 313 | 0.110 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1933 | 0.110 |
Why?
| | Necrosis | 1 | 2015 | 232 | 0.110 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2016 | 124 | 0.110 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 68 | 0.110 |
Why?
| | Cells, Cultured | 5 | 2019 | 4077 | 0.110 |
Why?
| | Vidarabine | 2 | 2018 | 30 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1949 | 0.110 |
Why?
| | Harringtonines | 1 | 2013 | 2 | 0.110 |
Why?
| | Tumor Suppressor Proteins | 1 | 2016 | 314 | 0.110 |
Why?
| | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2013 | 1 | 0.110 |
Why?
| | Alemtuzumab | 3 | 2007 | 15 | 0.110 |
Why?
| | Registries | 2 | 2023 | 1895 | 0.110 |
Why?
| | Gene Expression Profiling | 3 | 2019 | 1688 | 0.100 |
Why?
| | Glucose | 1 | 2018 | 1001 | 0.100 |
Why?
| | Phenotype | 2 | 2019 | 3074 | 0.100 |
Why?
| | Interleukin-1 | 1 | 2017 | 959 | 0.100 |
Why?
| | Carbon Monoxide | 1 | 2013 | 68 | 0.100 |
Why?
| | Pyridazines | 1 | 2013 | 54 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1344 | 0.100 |
Why?
| | Nausea | 1 | 2012 | 110 | 0.100 |
Why?
| | 5-Methylcytosine | 1 | 2012 | 20 | 0.100 |
Why?
| | Vomiting | 1 | 2012 | 128 | 0.100 |
Why?
| | Liver | 1 | 2020 | 1839 | 0.100 |
Why?
| | Biopsy | 1 | 2015 | 1092 | 0.090 |
Why?
| | Membrane Proteins | 1 | 2018 | 1117 | 0.090 |
Why?
| | Imidazoles | 1 | 2013 | 234 | 0.090 |
Why?
| | Incidence | 2 | 2016 | 2636 | 0.090 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 2 | 2023 | 33 | 0.090 |
Why?
| | Length of Stay | 1 | 2016 | 1120 | 0.090 |
Why?
| | Amino Acid Sequence | 2 | 2015 | 2056 | 0.090 |
Why?
| | Software | 1 | 2015 | 606 | 0.090 |
Why?
| | Fatigue | 1 | 2012 | 316 | 0.090 |
Why?
| | Dioxygenases | 1 | 2010 | 28 | 0.090 |
Why?
| | Sesquiterpenes | 2 | 2016 | 53 | 0.090 |
Why?
| | Oxidants | 1 | 2011 | 109 | 0.090 |
Why?
| | GTP-Binding Proteins | 1 | 2011 | 158 | 0.080 |
Why?
| | Chronic Disease | 1 | 2016 | 1716 | 0.080 |
Why?
| | Ethanol | 1 | 2015 | 589 | 0.080 |
Why?
| | Insulin Resistance | 1 | 2018 | 1165 | 0.080 |
Why?
| | Wasp Venoms | 1 | 2009 | 4 | 0.080 |
Why?
| | Protein Multimerization | 1 | 2011 | 178 | 0.080 |
Why?
| | Blast Crisis | 2 | 2025 | 33 | 0.080 |
Why?
| | Injections, Subcutaneous | 1 | 2009 | 147 | 0.080 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 318 | 0.080 |
Why?
| | Epinephrine | 1 | 2009 | 141 | 0.080 |
Why?
| | Mice, Transgenic | 3 | 2023 | 2117 | 0.080 |
Why?
| | Emergencies | 1 | 2009 | 155 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2010 | 221 | 0.080 |
Why?
| | Immunization Schedule | 1 | 2010 | 197 | 0.080 |
Why?
| | RNA, Small Interfering | 3 | 2016 | 591 | 0.070 |
Why?
| | Inflammation | 1 | 2019 | 2737 | 0.070 |
Why?
| | Melphalan | 1 | 2007 | 29 | 0.070 |
Why?
| | Blood Transfusion | 2 | 2020 | 295 | 0.070 |
Why?
| | Transplantation Chimera | 1 | 2007 | 54 | 0.070 |
Why?
| | Tumor Cells, Cultured | 2 | 2022 | 942 | 0.070 |
Why?
| | Mice, Inbred C57BL | 4 | 2020 | 5439 | 0.070 |
Why?
| | Karnofsky Performance Status | 1 | 2006 | 37 | 0.070 |
Why?
| | HEK293 Cells | 2 | 2019 | 696 | 0.070 |
Why?
| | Receptors, Thrombopoietin | 2 | 2016 | 5 | 0.060 |
Why?
| | Exome | 2 | 2018 | 220 | 0.060 |
Why?
| | Calreticulin | 2 | 2016 | 27 | 0.060 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2014 | 432 | 0.060 |
Why?
| | Janus Kinase 2 | 2 | 2016 | 32 | 0.060 |
Why?
| | Ganciclovir | 1 | 2006 | 52 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 712 | 0.060 |
Why?
| | Valine | 1 | 2006 | 81 | 0.060 |
Why?
| | Acyclovir | 1 | 2006 | 99 | 0.060 |
Why?
| | Philadelphia Chromosome | 2 | 2016 | 18 | 0.060 |
Why?
| | Risk Factors | 3 | 2014 | 9746 | 0.060 |
Why?
| | Cell Proliferation | 3 | 2020 | 2375 | 0.060 |
Why?
| | Bone Marrow Transplantation | 1 | 2006 | 275 | 0.060 |
Why?
| | Pedigree | 2 | 2015 | 486 | 0.060 |
Why?
| | Janus Kinases | 2 | 2015 | 12 | 0.060 |
Why?
| | Oxidation-Reduction | 2 | 2019 | 1028 | 0.060 |
Why?
| | Cytomegalovirus Infections | 1 | 2006 | 189 | 0.050 |
Why?
| | Diamines | 1 | 2023 | 3 | 0.050 |
Why?
| | Antigens, CD34 | 1 | 2023 | 88 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2016 | 812 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 2015 | 2140 | 0.050 |
Why?
| | Chemotaxis | 1 | 2023 | 129 | 0.050 |
Why?
| | Flow Cytometry | 2 | 2018 | 1155 | 0.050 |
Why?
| | Angiogenesis Inhibitors | 1 | 2004 | 220 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2010 | 1497 | 0.050 |
Why?
| | Neutropenia | 1 | 2022 | 136 | 0.050 |
Why?
| | Drug Interactions | 2 | 2013 | 393 | 0.050 |
Why?
| | Early Termination of Clinical Trials | 1 | 2021 | 15 | 0.050 |
Why?
| | Quinuclidines | 1 | 2020 | 9 | 0.040 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2020 | 72 | 0.040 |
Why?
| | Hyperbilirubinemia | 1 | 2020 | 11 | 0.040 |
Why?
| | Receptors, Cell Surface | 1 | 2022 | 380 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2006 | 712 | 0.040 |
Why?
| | Niacinamide | 1 | 2020 | 75 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1197 | 0.040 |
Why?
| | Neoplasms, Second Primary | 1 | 2021 | 106 | 0.040 |
Why?
| | Lentivirus | 1 | 2019 | 53 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2020 | 285 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 333 | 0.040 |
Why?
| | Daunorubicin | 1 | 2018 | 26 | 0.040 |
Why?
| | Consolidation Chemotherapy | 1 | 2018 | 9 | 0.040 |
Why?
| | Mice, Nude | 2 | 2015 | 682 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2018 | 22 | 0.040 |
Why?
| | Iron | 1 | 2020 | 281 | 0.040 |
Why?
| | Drug Monitoring | 1 | 2020 | 216 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2016 | 2871 | 0.040 |
Why?
| | Myeloablative Agonists | 1 | 2018 | 21 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 350 | 0.040 |
Why?
| | Cause of Death | 1 | 2020 | 392 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2018 | 109 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2019 | 184 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 301 | 0.040 |
Why?
| | Whole-Body Irradiation | 1 | 2018 | 76 | 0.040 |
Why?
| | Fetal Blood | 1 | 2020 | 317 | 0.040 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 181 | 0.040 |
Why?
| | Child | 2 | 2024 | 20785 | 0.040 |
Why?
| | HLA Antigens | 1 | 2019 | 234 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4057 | 0.040 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 15 | 0.040 |
Why?
| | Cell Count | 1 | 2018 | 311 | 0.040 |
Why?
| | Biological Transport | 1 | 2018 | 404 | 0.030 |
Why?
| | Glutathione | 1 | 2019 | 347 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2017 | 32 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1199 | 0.030 |
Why?
| | Retinal Dehydrogenase | 1 | 2017 | 30 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2018 | 239 | 0.030 |
Why?
| | Oxides | 1 | 2017 | 41 | 0.030 |
Why?
| | Glycolysis | 1 | 2018 | 311 | 0.030 |
Why?
| | Arsenicals | 1 | 2017 | 32 | 0.030 |
Why?
| | Benzothiazoles | 1 | 2016 | 32 | 0.030 |
Why?
| | Adenosine Triphosphate | 1 | 2019 | 478 | 0.030 |
Why?
| | NADP | 1 | 2016 | 46 | 0.030 |
Why?
| | Heterografts | 1 | 2017 | 131 | 0.030 |
Why?
| | Hydrazines | 1 | 2016 | 34 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 631 | 0.030 |
Why?
| | Cyclophosphamide | 1 | 2017 | 232 | 0.030 |
Why?
| | Deoxyglucose | 1 | 2016 | 52 | 0.030 |
Why?
| | Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2016 | 10 | 0.030 |
Why?
| | Drug Combinations | 1 | 2017 | 330 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2019 | 596 | 0.030 |
Why?
| | Transcriptome | 1 | 2022 | 874 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 428 | 0.030 |
Why?
| | Sample Size | 1 | 2016 | 116 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2017 | 218 | 0.030 |
Why?
| | Kinetics | 1 | 2019 | 1644 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2017 | 275 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2023 | 899 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 286 | 0.030 |
Why?
| | Isoenzymes | 1 | 2016 | 302 | 0.030 |
Why?
| | Splenomegaly | 1 | 2015 | 16 | 0.030 |
Why?
| | Metabolome | 1 | 2018 | 338 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2018 | 497 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2017 | 360 | 0.030 |
Why?
| | Repressor Proteins | 1 | 2018 | 406 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2017 | 374 | 0.030 |
Why?
| | Comorbidity | 2 | 2013 | 1544 | 0.030 |
Why?
| | Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
| | Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
| | Hydroxyurea | 1 | 2015 | 34 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1432 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2015 | 376 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2017 | 372 | 0.030 |
Why?
| | Imatinib Mesylate | 1 | 2014 | 76 | 0.030 |
Why?
| | Quality of Life | 2 | 2016 | 2687 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 68 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2022 | 1887 | 0.030 |
Why?
| | Sirolimus | 1 | 2016 | 266 | 0.030 |
Why?
| | Immunologic Factors | 1 | 2017 | 230 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2015 | 372 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 201 | 0.030 |
Why?
| | Dasatinib | 1 | 2014 | 54 | 0.030 |
Why?
| | Age of Onset | 1 | 2015 | 496 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2015 | 548 | 0.030 |
Why?
| | Thiazoles | 1 | 2014 | 117 | 0.030 |
Why?
| | Research Design | 1 | 2020 | 1043 | 0.030 |
Why?
| | Genetic Heterogeneity | 1 | 2014 | 58 | 0.030 |
Why?
| | Leukemia, Lymphoid | 1 | 2013 | 27 | 0.030 |
Why?
| | Trans-Activators | 1 | 2016 | 388 | 0.030 |
Why?
| | Drug Synergism | 1 | 2014 | 370 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 839 | 0.030 |
Why?
| | Cyclosporine | 1 | 2014 | 263 | 0.030 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2013 | 74 | 0.030 |
Why?
| | RNA Interference | 1 | 2014 | 450 | 0.030 |
Why?
| | Phosphorylation | 1 | 2017 | 1710 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2063 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2015 | 1247 | 0.020 |
Why?
| | Homeodomain Proteins | 1 | 2016 | 495 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2015 | 569 | 0.020 |
Why?
| | Thrombosis | 1 | 2015 | 343 | 0.020 |
Why?
| | Leupeptins | 1 | 2011 | 9 | 0.020 |
Why?
| | HL-60 Cells | 1 | 2011 | 34 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2013 | 583 | 0.020 |
Why?
| | Proteasome Inhibitors | 1 | 2011 | 42 | 0.020 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2011 | 50 | 0.020 |
Why?
| | Mitoxantrone | 1 | 2010 | 14 | 0.020 |
Why?
| | Free Radical Scavengers | 1 | 2011 | 82 | 0.020 |
Why?
| | Genotype | 1 | 2015 | 1835 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2015 | 2835 | 0.020 |
Why?
| | Etoposide | 1 | 2010 | 148 | 0.020 |
Why?
| | Prospective Studies | 2 | 2016 | 7123 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2011 | 148 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 2011 | 170 | 0.020 |
Why?
| | Acetylcysteine | 1 | 2011 | 146 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2554 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2011 | 361 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1722 | 0.020 |
Why?
| | Treatment Failure | 1 | 2010 | 339 | 0.020 |
Why?
| | Insulin | 1 | 2018 | 2325 | 0.020 |
Why?
| | RNA-Binding Proteins | 1 | 2011 | 387 | 0.020 |
Why?
| | Nitroimidazoles | 1 | 2004 | 9 | 0.010 |
Why?
| | Cyclohexanes | 1 | 2004 | 22 | 0.010 |
Why?
| | Fluorescein | 1 | 2004 | 24 | 0.010 |
Why?
| | In Situ Nick-End Labeling | 1 | 2004 | 124 | 0.010 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2004 | 39 | 0.010 |
Why?
| | Lectins | 1 | 2004 | 48 | 0.010 |
Why?
| | Microcirculation | 1 | 2004 | 145 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 2004 | 256 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 2004 | 296 | 0.010 |
Why?
| | Capillaries | 1 | 2004 | 103 | 0.010 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2004 | 123 | 0.010 |
Why?
| | Angiography | 1 | 2004 | 196 | 0.010 |
Why?
| | Wilms Tumor | 1 | 2004 | 77 | 0.010 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 296 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2004 | 530 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2004 | 1691 | 0.010 |
Why?
| | Hypoxia | 1 | 2004 | 1084 | 0.010 |
Why?
|
|
Pollyea's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|